Omblastys (iodine (131I) omburtamab)
Orphan
- Region
- 🇪🇺 EU
- Active substance
- iodine (131I) omburtamab
- Company
- Y-Mabs Therapeutics A/S
- Status
- Refused
- Therapeutic area
- Neuroblastoma
- CHMP opinion
- Thu 15 Dec 2022
- Designations
- Orphan
- Application
- EMEA/H/C/005499
- ATC
- V10XA
- Official record
- www.ema.europa.eu
Indication
Treatment of neuroblastoma.
Regulatory milestones
No milestones recorded in the last year.
Follow Omblastys
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.